Advances in the treatment of central serous chorioretinopathy
10.3980/j.issn.1672-5123.2020.1.18
- VernacularTitle:中心性浆液性脉络膜视网膜病变的治疗进展
- Author:
Lian Chen
1
Author Information
1. Xi'an No.3 Hospital, the Affiliated Hospital of Northwest University, Xi'an 710018, Shaanxi Province China
- Publication Type:Journal Article
- Keywords:
chorioretinopathy;
photocoagulation;
photodynamic therapy;
medicine
- From:
International Eye Science
2020;20(1):79-82
- CountryChina
- Language:Chinese
-
Abstract:
Central serous chorioretinopathy(CSC)is a disease that associated with multifactors. The specific pathogenesis is not yet clear. Except for subthreshold micropulse laser treatment and reduced dose photodynamic therapy(PDT), drugs based on etiology of CSC, such as anti-vascular endothelial growth factor(VEGF), methotrexate, eplerenone, anti-helicobacter pylori, have been applied to experimental treatment. The purpose of this article is to review the literature in the treatment of CSC, and to provide reference for clinical treatment of CSC.
- Full text:202001018.pdf
